E A Swallow1, M W Aref1, N Chen2, I Byiringiro1, M A Hammond1,3, B P McCarthy4, P R Territo4, M M Kamocka2, S Winfree2, K W Dunn2, S M Moe2,5, M R Allen6,7,8,9. 1. Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Dr, Indianapolis, IN, 46202, USA. 2. Department of Medicine - Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA. 3. School of Mechanical Engineering, Purdue University, West Lafayette, IN, USA. 4. Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, USA. 5. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA. 6. Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Dr, Indianapolis, IN, 46202, USA. matallen@iupui.edu. 7. Department of Medicine - Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA. matallen@iupui.edu. 8. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA. matallen@iupui.edu. 9. Department of Biomedical Engineering, Indiana University Purdue University of Indianapolis, Indianapolis, IN, USA. matallen@iupui.edu.
Abstract
This work examines the skeletal accumulation of fluorescently tagged zoledronate in an animal model of chronic kidney disease. The results show higher accumulation in 24-h post-dose animals with lower kidney function due to greater amounts of binding at individual surfaces. INTRODUCTION: Chronic kidney disease (CKD) patients suffer from increased rates of skeletal-related mortality from changes driven by biochemical abnormalities. Bisphosphonates are commonly used in reducing fracture risk in a variety of diseases, yet their use is not recommended in advanced stages of CKD. This study aimed to characterize the accumulation of a single dose of fluorescently tagged zoledronate (FAM-ZOL) in the setting of reduced kidney function. METHODS: At 25 weeks of age, FAM-ZOL was administered to normal and CKD rats. Twenty-four hours later, multiple bones were collected and assessed using bulk fluorescence imaging, two-photon imaging, and dynamic histomorphometry. RESULTS: CKD animals had significantly higher levels of FAM-ZOL accumulation in the proximal tibia, radius, and ulna, but not in lumbar vertebral body or mandible, based on multiple measurement modalities. Although a majority of trabecular bone surfaces were covered with FAM-ZOL in both normal and CKD animals, the latter had significantly higher levels of fluorescence per unit bone surface in the proximal tibia. CONCLUSIONS: These results provide new data regarding how reduced kidney function affects drug accumulation in rat bone.
This work examines the skeletal accumulation of fluorescently tagged zoledronate in an animal model of chronic kidney disease. The results show higher accumulation in 24-h post-dose animals with lower kidney function due to greater amounts of binding at individual surfaces. INTRODUCTION:Chronic kidney disease (CKD) patients suffer from increased rates of skeletal-related mortality from changes driven by biochemical abnormalities. Bisphosphonates are commonly used in reducing fracture risk in a variety of diseases, yet their use is not recommended in advanced stages of CKD. This study aimed to characterize the accumulation of a single dose of fluorescently tagged zoledronate (FAM-ZOL) in the setting of reduced kidney function. METHODS: At 25 weeks of age, FAM-ZOL was administered to normal and CKD rats. Twenty-four hours later, multiple bones were collected and assessed using bulk fluorescence imaging, two-photon imaging, and dynamic histomorphometry. RESULTS: CKD animals had significantly higher levels of FAM-ZOL accumulation in the proximal tibia, radius, and ulna, but not in lumbar vertebral body or mandible, based on multiple measurement modalities. Although a majority of trabecular bone surfaces were covered with FAM-ZOL in both normal and CKD animals, the latter had significantly higher levels of fluorescence per unit bone surface in the proximal tibia. CONCLUSIONS: These results provide new data regarding how reduced kidney function affects drug accumulation in rat bone.
Entities:
Keywords:
Bisphosphonate; Bone; CKD; Drug accumulation
Authors: Frank H Ebetino; Anne-Marie L Hogan; Shuting Sun; Maria K Tsoumpra; Xuchen Duan; James T Triffitt; Aaron A Kwaasi; James E Dunford; Bobby L Barnett; Udo Oppermann; Mark W Lundy; Alan Boyde; Boris A Kashemirov; Charles E McKenna; R Graham G Russell Journal: Bone Date: 2011-04-09 Impact factor: 4.398
Authors: Sharon M Moe; J Scott Radcliffe; Kenneth E White; Vincent H Gattone; Mark F Seifert; Xianming Chen; Blaire Aldridge; Neal X Chen Journal: J Bone Miner Res Date: 2011-11 Impact factor: 6.741
Authors: Anke J Roelofs; Charlotte A Stewart; Shuting Sun; Katarzyna M Błażewska; Boris A Kashemirov; Charles E McKenna; R Graham G Russell; Michael J Rogers; Mark W Lundy; Frank H Ebetino; Fraser P Coxon Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: Andrew W Y Shih; Matthew A Weir; Kristin K Clemens; Zhan Yao; Tara Gomes; Muhammad M Mamdani; David N Juurlink; Amanda Hird; Anthony Hodsman; Chirag R Parikh; Ron Wald; Suzanne M Cadarette; Amit X Garg Journal: Kidney Int Date: 2012-06-13 Impact factor: 10.612
Authors: Kenneth M Kozloff; Luisa Quinti; Somying Patntirapong; Peter V Hauschka; Ching-Hsuan Tung; Ralph Weissleder; Umar Mahmood Journal: Bone Date: 2008-10-22 Impact factor: 4.398
Authors: Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen Journal: Bone Date: 2019-07-09 Impact factor: 4.398
Authors: Elizabeth A Swallow; Corinne E Metzger; Neal X Chen; Joseph M Wallace; Samantha P Tippen; Rachel Kohler; Sharon M Moe; Matthew R Allen Journal: Bone Rep Date: 2022-02-07